BioCentury on BioBusiness,
Product Discovery & Development
A blood-letting problem
Monday, March 19, 2001
It sometimes happens that protocols designed to help patients turn out to do more harm than good. That apparently was the case in a Phase III trial of Alliance Pharmaceutical Corp.'s Oxygent blood substitute in cardiac bypass surgery patients. The good news for ALLP is that Oxygent itself apparently was not responsible for the higher incidence of stroke in treated patients versus controls. The bad news is that the company is likely to do a new Phase III study, which would set back its timeline for completing Phase III trials by about 18 months.
In January, ALLP voluntarily suspended enrollment in a Phase III trial of the perflubron emulsion blood substitute in patients undergoing cardiac surgery with cardiopulmonary bypass (CB) after seeing a higher incidence of stroke in treated patients. ALLP said the control group also experienced a lower-than-expected incidence of stroke (see BioCentury, Jan. 16).
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]